CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
What is the current institutional and insider ownership, and are there any notable changes following the announcement?
How does CYTX’s valuation (e.g., market cap, price‑to‑sales multiple) compare to peers developing oncology ADCs?
What risk factors (e.g., trial enrollment, safety concerns, competitive landscape) could negatively affect the stock’s upside?
14 days ago